#USA #Washington D.C. #Implantica #GERD #RefluxStop

Implantica Launches RefluxStop® in the U.S. Market

Implantica AG, a pioneering medtech company, has made significant strides in the treatment of gastroesophageal reflux disease (GERD) with the unveiling of its innovative product, RefluxStop®, during the 2026 American Foregut Society (AFS) Annual Meeting held in Washington D.C. This event marked a pivotal moment for the company as it introduced its FDA-approved solution to a captivated audience of leading surgeons and gastroenterologists.

The RefluxStop® device stands out by employing a unique mechanism designed to address the root cause of acid reflux while preserving the body's natural anatomy. In contrast to traditional surgical methods that involve encircling the esophagus to prevent reflux, the RefluxStop® procedure aims to restore perfect function of the lower esophageal sphincter without the associated complications like swallowing difficulties or the inability to belch—common issues arising from conventional anti-reflux surgeries.

During the panel discussion at the AFS meeting, which was significantly overbooked, more than 120 attendees, including esteemed professionals from both the U.S. and Europe, gathered to learn about how RefluxStop® could redefine GERD treatment. Moderated by Dr. John Lipham, a respected figure and past president of the AFS, the session addressed compelling clinical outcomes which have shown RefluxStop® to be not only highly effective but also drastically different from existing methods.

Dr. Lipham remarked, "The FDA's PMA approval of RefluxStop signifies a monumental shift in GERD treatment over the past seven decades. The engaging interest displayed by my peers reflects a noteworthy advancement in patient care possibilities."

The gathering also saw discussions from a panel of top experts including Dr. Christy Dunst from California, and Dr. Peter Kahrilas from Northwestern University, who underscored the progressive understanding of this new therapeutic method. With clinical trials documenting five-year positive outcomes from over 60 centers in Europe, the RefluxStop® system is backed by data signifying its effectiveness in addressing refractory GERD symptoms that plague many U.S. patients, with approximately 40% still suffering despite medication.

The allure of RefluxStop® and its introduction to U.S. healthcare comes at a crucial time. Many gastroesophageal reflux disease sufferers have not been responsive to traditional therapies, which often involve invasive procedures leading to undesirable side effects. As per Dr. Peter Forsell, Implantica's Founder and CEO, the remarkable engagement at the AFS meeting signified a significant unmet demand within this therapeutic area.

"With many patients struggling to find relief even while on daily medications, we are confident that RefluxStop® will fill an existing void in GERD treatment options, establishing a new standard of care," stated Forsell.

Following this successful launch, Implantica is now gearing up for a systematic rollout across the U.S., collaborating with leading medical professionals and institutions eager to incorporate RefluxStop® into their practice.

In addition to its revolutionary approach to GERD, Implantica is currently developing two additional platform technologies aimed at enhancing patient care through advanced implantable solutions capable of remote monitoring and adjustments—an avenue that incorporates eHealth applications and wireless energy transfer.

As the RefluxStop® innovation unfolds, it paints a promising future for millions of GERD patients seeking effective and less intrusive treatment alternatives—truly a testament to the advancement of medical technology and patient-centered care.